Cystic Fibrosis: NovaBiotics Advances Old Dog With New Tricks

 
• By Eleanor Malone
  
Generate a summary of this article
Listen to this article
Beta

Lynovex, a reformulated version of a molecule which has been around for decades for a rare metabolic disease, has just succeeded in a Phase IIb study to treat exacerbations in cystic fibrosis. The mutation-agnostic therapy could improve on current treatments for breakthrough exacerbations, and reduce the associated long-term damaged.

Dog
Full speed ahead for Lynovex after Phase IIb • Source: Shutterstock

NovaBiotics Ltd. is making plans to progress its oral treatment for cystic fibrosis exacerbations into Phase III by early next year, after reporting positive Phase IIb results. The company is hopeful that it will be able to file for approval of Lynovex (cysteamine) in 2020 should Phase III studies prove positive. It sees its therapy for acute use as complementary to other approaches to treating and managing CF.

CEO Deborah O'Neil told Scrip that the treatment had the potential to provide better control of CF exacerbations than current...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Respiratory

Cagrisema Leads The Charge For 2025

 
• By Elizabeth Cairns

2030 sales forecasts for Novo’s obesity hope are an order of magnitude larger than its closest rival among 2025’s expected debutantes.  

As More DLL3 Bispecifics Advance, Doctors Are Adjusting To CRS, ICANS

 
• By Mandy Jackson

Amgen’s Imdelltra for small-cell lung cancer is one of two bispecific T-cell engagers approved for solid tumors, but data at the WCLC meeting show other DLL3-targeting BiTEs may be on the way.

Novo Nordisk’s Semaglutide Shows Promise In Hidradenitis Suppurativa

 
• By Andrew McConaghie

An academic study of GLP-1 agonist showed promise in patients with the painful skin condition but with no signs that the Danish drugmaker will pursue the indication, smaller players in the space may be interested.

Syros’s AML Failure Sparks MDS Program Jitters, But Fears May Be Overblown

 
• By Alaric DeArment

Discontinuation of the AML study created concern about potential readthrough to a pivotal MDS trial, but the company and analysts pointed out differences in the diseases.

More from Therapeutic Category

Scrip Data Article Without An Author

"Neque porro quisquam est qui dolorem ipsum quia dolor sit amet, consectetur, adipisci velit..."

Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]

Pipelines in bioconjugates continue to develop, from ADCs to XDCs, with radionuclide drug conjugates (RDCs) and antibody-oligonucleotide conjugates (AOCs) leading the expansion.

Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.